An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF

Stopped early · Phase 3

Conditions studied: Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Lung Disease

In brief

Open-label therapy will be administered to up to 220 patients, following completion of either InterMune Protocol GIPF-002 Part B or Protocol GIPF-004, to assess the long-term safety of subcutaneous Interferon gamma-1b. The study duration will be 5 years.

Key facts

Study ID

NCT00076635

Run by

InterMune

People needed

91

Starts

2003-11-01

Expected to finish

2007-04-01

Last updated by the study team

2007-11-06

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Enrollment in Protocol GIPF 002 Part B or GIPF-004
• Completion of the End of Treatment Visit in Protocol GIPF-002 Part B or the Study Completion Visit in GIPF-004
• Able to understand and sign a written informed consent form and comply with the requirements of the study

You may not qualify if…

• pregnancy or lactation
• lack of adherence to either GIPF-002 or GIPF-004 study protocols and treatment regimens
• if Principal Investigator deems patient is unsuitable for study

Where it is running

• Intermune Inc — Brisbane, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.